FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE

N/A

Manufactured by HyVee Inc

604 FDA adverse event reports analyzed

Last updated: 2026-04-15

About FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE

FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by HyVee Inc. The most commonly reported adverse reactions for FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE include DRUG INEFFECTIVE, CHRONIC KIDNEY DISEASE, DRUG EFFECT LESS THAN EXPECTED, RENAL FAILURE, ACUTE KIDNEY INJURY. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE.

Top Adverse Reactions

DRUG INEFFECTIVE70 reports
CHRONIC KIDNEY DISEASE53 reports
DRUG EFFECT LESS THAN EXPECTED28 reports
RENAL FAILURE27 reports
ACUTE KIDNEY INJURY23 reports
OFF LABEL USE22 reports
GASTROOESOPHAGEAL REFLUX DISEASE15 reports
END STAGE RENAL DISEASE14 reports
EXPIRED PRODUCT ADMINISTERED14 reports
NAUSEA12 reports
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS12 reports
INCORRECT DOSE ADMINISTERED10 reports
ABDOMINAL PAIN UPPER9 reports
DIARRHOEA9 reports
DYSGEUSIA9 reports
PRODUCT AFTER TASTE9 reports
RENAL INJURY9 reports
RENAL IMPAIRMENT8 reports
ANXIETY7 reports
DEPRESSION7 reports
DYSPNOEA7 reports
HEADACHE7 reports
MALAISE7 reports
ABDOMINAL DISCOMFORT6 reports
CONDITION AGGRAVATED6 reports
DIZZINESS6 reports
INCORRECT PRODUCT ADMINISTRATION DURATION6 reports
REBOUND ACID HYPERSECRETION6 reports
THERAPEUTIC PRODUCT EFFECT INCOMPLETE6 reports
DEATH5 reports
NEPHROGENIC ANAEMIA5 reports
UNDERDOSE5 reports
CHEST PAIN4 reports
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION4 reports
DYSPEPSIA4 reports
FATIGUE4 reports
HYPERPARATHYROIDISM SECONDARY4 reports
HYPERTENSION4 reports
INCORRECT DRUG ADMINISTRATION DURATION4 reports
INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS4 reports
MIGRAINE4 reports
THERAPEUTIC RESPONSE UNEXPECTED4 reports
TUBULOINTERSTITIAL NEPHRITIS4 reports
VOMITING4 reports
CONSTIPATION3 reports
DRUG ADMINISTRATION ERROR3 reports
HOSPITALISATION3 reports
HYPERCHLORHYDRIA3 reports
HYPERSENSITIVITY3 reports
ILLNESS3 reports
NEPHROPATHY3 reports
PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE3 reports
RASH3 reports
REACTION TO SWEETENER3 reports
RENAL HAEMANGIOMA3 reports
THERAPEUTIC PRODUCT EFFECT DECREASED3 reports
THROAT IRRITATION3 reports
TOOTH FRACTURE3 reports
ABDOMINAL DISTENSION2 reports
ACCIDENTAL EXPOSURE TO PRODUCT PACKAGING2 reports
BLOOD GLUCOSE INCREASED2 reports
CHILLS2 reports
CHRONIC KIDNEY DISEASE MINERAL AND BONE DISORDER2 reports
CHRONIC OBSTRUCTIVE PULMONARY DISEASE2 reports
CORONARY ARTERY DISEASE2 reports
DECREASED APPETITE2 reports
DRUG EFFECT DECREASED2 reports
DRY MOUTH2 reports
FEELING ABNORMAL2 reports
FLATULENCE2 reports
GASTRIC CANCER2 reports
GASTROINTESTINAL DISORDER2 reports
HYPERKALAEMIA2 reports
INSOMNIA2 reports
LOSS OF CONSCIOUSNESS2 reports
LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES2 reports
LUNG DISORDER2 reports
MUSCLE SPASMS2 reports
NEOPLASM MALIGNANT2 reports
ORAL DISCOMFORT2 reports
PAIN2 reports
PANCREATITIS2 reports
PRODUCT DOSE OMISSION ISSUE2 reports
PRODUCTIVE COUGH2 reports
RENAL DISORDER2 reports
STRESS2 reports
THERAPEUTIC PRODUCT EFFECT DELAYED2 reports
TOOTH DISORDER2 reports
TREMOR2 reports
URTICARIA2 reports
WEIGHT DECREASED2 reports
ACCIDENTAL EXPOSURE TO PRODUCT BY CHILD1 reports
ADVERSE DRUG REACTION1 reports
ADVERSE EVENT1 reports
AGEUSIA1 reports
AGGRESSION1 reports
AMNESIA1 reports
APHTHOUS STOMATITIS1 reports
ARTHRALGIA1 reports
ASTHENIA1 reports

Report Outcomes

Out of 326 classified reports for FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE:

Serious 25.5%Non-Serious 74.5%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female148 (66.4%)
Male75 (33.6%)

Reports by Age

Age 657 reports
Age 535 reports
Age 685 reports
Age 384 reports
Age 524 reports
Age 614 reports
Age 644 reports
Age 674 reports
Age 273 reports
Age 573 reports
Age 603 reports
Age 633 reports
Age 663 reports
Age 723 reports
Age 803 reports
Age 813 reports
Age 863 reports
Age 873 reports
Age 112 reports
Age 132 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE?

This profile reflects 604 FDA FAERS reports that mention FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE?

Frequently reported terms in FAERS include DRUG INEFFECTIVE, CHRONIC KIDNEY DISEASE, DRUG EFFECT LESS THAN EXPECTED, RENAL FAILURE, ACUTE KIDNEY INJURY, OFF LABEL USE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE?

Labeling and FAERS entries often list HyVee Inc in connection with FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.